|
Samuel P. Wertheimer, Ph.D., Dr. Wertheimer joined OrbiMed in 2000 and is a Principal in the private equity funds management group. Dr. Wertheimer’s prior experience includes work in biotechnology finance, technology transfer, intellectual property and research in immunology and molecular biology. Dr. Wertheimer was a Fellow at the Memorial Sloan-Kettering Cancer Center. Dr. Wertheimer received a Ph.D. in Molecular Biology from New York University, an M.P.H. from Yale University and a B.A. from The Johns Hopkins University. He has served as a Director of Salmedix and Corus Pharma and currently serves on the boards of several private biotechnology companies including Biodel and ChemoCentryx. | 